# Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and *MAPT* Sub-haplotypes

Hui Wang<sup>1,2</sup>, PhD; Timothy S Chang<sup>3</sup>, MD, PhD; Beth A Dombroski<sup>1,2</sup>, PhD; Po-Liang Cheng<sup>1,2</sup>, PhD; 3 Ya-Qin Si<sup>4</sup>, PhD; Albert Tucci<sup>4</sup>, PhD; Vishakha Patil<sup>5</sup>, MS; Leopoldo Valiente-Banuet<sup>5</sup>, MS; Kurt 4 Farrell<sup>6</sup>, PhD; Catriona Mclean<sup>7</sup>, MD; Laura Molina-Porcel<sup>8,9</sup>, MD, PhD; Alex Rajput<sup>10</sup>, MD; Peter Paul 5 De Deyn<sup>11,12</sup>, MD, PhD; Nathalie Le Bastard<sup>13</sup>, PhD; Marla Gearing<sup>14</sup>, PhD; Laura Donker Kaat<sup>15</sup>, MD, 6 PhD; John C Van Swieten<sup>15</sup>, MD, PhD; Elise Dopper<sup>15</sup>, MD, PhD; Bernardino F Ghetti<sup>16</sup>, MD; Kathy L 7 Newell<sup>16</sup>, MD; Claire Troakes<sup>17</sup>, PhD; Justo G de Yébenes<sup>18</sup>, MD, PhD; Alberto Rábano-Gutierrez<sup>19</sup>, 8 MD, PhD; Tina Meller<sup>20</sup>, PhD; Wolfgang H Oertel<sup>20</sup>, MD, PhD; Gesine Respondek<sup>21</sup>, MD; Maria 9 Stamelou<sup>22,23</sup>, MD; Thomas Arzberger<sup>24,25</sup>, MD; Sigrun Roeber<sup>26</sup>, MD; Ulrich Müller<sup>26</sup>, MD; Franziska 10 Hopfner<sup>44</sup>, MD; Pau Pastor<sup>27,28</sup>, MD, PhD; Alexis Brice<sup>29</sup>, MD; Alexandra Durr<sup>29</sup>, MD, PhD; Isabelle Le 11 Ber<sup>29</sup>, MD, PhD; Thomas G Beach<sup>30</sup>, MD, PhD; Geidy E Serrano<sup>30</sup>, PhD; Lili-Naz Hazrati<sup>31</sup>, MD, PhD; 12 Irene Litvan<sup>32</sup>, MD; Rosa Rademakers<sup>33,34</sup>, PhD; Owen A Ross<sup>34</sup>, PhD; Douglas Galasko<sup>32</sup>, MD; Adam 13 L Boxer<sup>35</sup>, MD, PhD; Bruce L Miller<sup>35</sup>, MD; Willian W Seeley<sup>35</sup>, MD; Vivianna M Van Deerlin<sup>1</sup>, MD, 14 PhD; Edward B Lee<sup>1,36</sup>, MD, PhD; Charles L White III<sup>37</sup>, MD; Huw R Morris<sup>38</sup>, MD, PhD; Rohan de 15 Silva<sup>39</sup>, PhD; John F Crary<sup>6</sup>, MD, PhD; Alison M Goate<sup>40</sup>, PhD; Jeffrey S Friedman<sup>41</sup>, MD, PhD; Yuk 16 Yee Leung<sup>1,2</sup>, PhD; Giovanni Coppola<sup>5,42</sup>, MD; Adam C Naj<sup>1,2,43</sup>, PhD; Li-San Wang<sup>1,2</sup>, PhD; PSP 17 genetics study group; Dennis W Dickson<sup>34</sup>, MD; Günter U Höglinger<sup>44</sup>, MD; Jung-Ying Tzeng<sup>4,45</sup>, PhD; 18 Daniel H Geschwind<sup>5,46,47</sup>, MD, PhD; Gerard D Schellenberg<sup>1,2</sup>, PhD; Wan-Ping Lee<sup>1,2</sup>, PhD 19 20

- <sup>1</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of
   Pennsylvania, Philadelphia, PA, USA
- <sup>2</sup>Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania,
   Philadelphia, PA, USA
- <sup>3</sup>Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
- 26 University of California, Los Angeles, Los Angeles, CA, USA
- <sup>4</sup>Bioinformatics Research Center, North Carolina State University, NC, USA
- <sup>5</sup>Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
- 29 University of California, Los Angeles, Los Angeles, CA, USA

- <sup>6</sup>Department of Pathology, Department of Artificial Intelligence & Human Health, Nash Family,
- 31 Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain,
- 32 Institute, Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai,
- 33 New York, NY, USA.
- <sup>7</sup>Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria,
   Australia
- <sup>8</sup>Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic,
- Fundació Recerca Clínic Barcelona (FRCB). Institut d'Investigacions Biomediques August Pi i Sunyer
   (IDIBAPS), University of Barcelona, Barcelona, Spain
- <sup>9</sup>Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain
- 40 <sup>10</sup>Movement Disorders Program, Division of Neurology, University of Saskatchewan, Saskatoon,
- 41 Saskatchewan, Canada
- 42 <sup>11</sup>Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, University of Antwerp,
- 43 Wilrijk (Antwerp), Belgium
- <sup>12</sup>Department of Neurology, University Medical Center Groningen, NL-9713 AV Groningen,
- 45 Netherlands
- 46 <sup>13</sup>Fujirebio Europe NV, Technologiepark 6, 9052 Gent, Belgium
- <sup>14</sup>Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University
  School of Medicine, Atlanta, GA, USA
- 49 <sup>15</sup>Netherlands Brain Bank and Erasmus University, Netherlands
- <sup>16</sup>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
- 51 Indianapolis, IN, USA
- <sup>17</sup>London Neurodegenerative Diseases Brain Bank, King's College London, London, UK
- <sup>18</sup>Autonomous University of Madrid, Madrid, Spain
- <sup>19</sup>Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas) Centro Alzheimer
- 55 Fundación Reina Sofía, Madrid, Spain
- <sup>20</sup>Department of Neurology, Philipps-Universität, Marburg, Germany
- 57 <sup>21</sup>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- 58 <sup>22</sup>Parkinson's disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece
- 59 <sup>23</sup>European University of Cyprus, Nicosia, Cyprus
- 60 <sup>24</sup>Department of Psychiatry and Psychotherapy, University Hospital Munich,
- 61 Ludwig-Maximilians-University Munich, Germany
- 62 <sup>25</sup>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Germany
- 63 <sup>26</sup>German Brain Bank, Neurobiobank Munich, Germany
- <sup>27</sup>Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i
   Pujol, Badalona, Barcelona, Spain
- <sup>28</sup>Neurosciences, The Germans Trias i Pujol Research Institute (IGTP) Badalona, Badalona, Spain
- 67 <sup>29</sup>Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR
- 68 7225, APHP Hôpital Pitié-Salpêtrière, Paris, France

- <sup>30</sup>Banner Sun Health Research Institute, Sun City, AZ, USA
- <sup>31</sup>University McGill, Montreal, Quebec, Canada
- <sup>32</sup>Department of Neuroscience, University of California, San Diego, CA, USA
- <sup>33</sup>VIB Center for Molecular Neurology, University of Antwerp, Belgium
- 73 <sup>34</sup>Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA
- <sup>35</sup>Memory and Aging Center, University of California, San Francisco, CA, USA
- <sup>36</sup>Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine,
- 76 Philadelphia, PA, USA
- <sup>37</sup>University of Texas Southwestern Medical Center, Dallas, TX, USA
- <sup>38</sup>Departmento of Clinical and Movement Neuroscience, University College of London, London, UK
- <sup>39</sup>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.
- <sup>40</sup>Department of Genetics and Genomic Sciences, New York, NY, USA; Icahn School of Medicine at
- 81 Mount Sinai, New York, NY, USA
- 82 <sup>41</sup>Friedman Bioventure, Inc., Del Mar, CA, USA
- 83 Department of Genetics and Genomic Sciences, New York, NY, USA
- <sup>42</sup>Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of
- 85 California, Los Angeles, CA, USA
- <sup>43</sup>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University
   of Pennsylvania, Philadelphia, PA, USA
- <sup>44</sup>Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU)
- 89 München; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich
- 90 Cluster for Systems Neurology (SyNergy), Munich, Germany
- 91 <sup>45</sup>Department of Statistics, North Carolina State University, NC, USA
- 92 <sup>46</sup>Department of Human Genetics, David Geffen School of Medicine, University of California, Los
- 93 Angeles, Los Angeles, CA, USA
- <sup>47</sup>Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA
- 95

# 96 Search Terms:

- 97 Progressive Supranuclear Palsy (PSP), H1 and H2 haplotypes, MAPT, Copy number variation (CNV),
- 98 17q21.31
- 99100 Word Count: 3902 (Key Points, Abstract, and Main Text)
- 101

# 102 **Corresponding Author:**

- 103 Wan-Ping Lee
- 104 D103 Medical Research Laboratories, University of Pennsylvania,
- 105 3700 Hamilton Walk, Philadelphia, PA 19104, USA
- 106 Phone: +1 412-880-8674
- 107 Email: wan-ping.lee@pennmedicine.upenn.edu

108

109 Statistical Analysis conducted by Hui Wang, Ph.D., University of Pennsylvania

# 110 Key Points

111	<b>Question</b> : Do large copy number variations (i.e., $\alpha$ , $\beta$ , and $\gamma$ ) inside 17q21.31 contribute to the risk of
112	progressive supranuclear palsy (PSP) independently from the H1 and H2 haplotypes? Do structural
113	forms of 17q21.31, characterized by combinations of $\alpha$ , $\beta$ , and $\gamma$ , present divergent risk to the
114	development of PSP? Are structural forms of 17q21.31 associated with MAPT sub-haplotypes, such as
115	H1c?
116	Findings: In this case-control study of 1,684 individuals with PSP and 2,392 control subjects, the copy
117	number of $\gamma$ duplication was independently associated with the risk of the disease. H1 haplotypes with
118	more $\gamma$ duplications (H1 $\beta$ 1 $\gamma$ 2, H1 $\beta$ 1 $\gamma$ 3, and H1 $\beta$ 1 $\gamma$ 4) displayed a higher odds ratio for PSP when
119	compared to H1 $\beta$ 1 $\gamma$ 1. Notably, H1 $\beta$ 1 $\gamma$ 3 was observed to be in linkage disequilibrium with H1c, a widely
120	recognized MAPT sub-haplotype associated with PSP.
121	Meaning: The association between the H1 and H2 haplotypes and PSP involves multiple contributing

122 factors, including the copy number of  $\gamma$  duplication.

#### 123 Abstract

124	Importance: The chromosome 17q21.31 region, containing a 900 Kb inversion that defines H1 and H2
125	haplotypes, represents the strongest genetic risk locus in progressive supranuclear palsy (PSP). In
126	addition to H1 and H2, various structural forms of 17q21.31, characterized by the copy number of $\alpha$ , $\beta$ ,
127	and $\gamma$ duplications, have been identified. However, the specific effect of each structural form on the risk
128	of PSP has never been evaluated in a large cohort study.
129	
130	Objective: To assess the association of different structural forms of 17q.21.31, defined by the copy
131	numbers of $\alpha$ , $\beta$ , and $\gamma$ duplications, with the risk of PSP and <i>MAPT</i> sub-haplotypes.
132	
133	Design, setting, and participants: Utilizing whole genome sequencing data of 1,684 (1,386 autopsy
134	confirmed) individuals with PSP and 2,392 control subjects, a case-control study was conducted to
135	investigate the association of copy numbers of $\alpha$ , $\beta$ , and $\gamma$ duplications and structural forms of 17q21.31
136	with the risk of PSP. All study subjects were selected from the Alzheimer's Disease Sequencing Project
137	(ADSP) Umbrella NG00067.v7. Data were analyzed between March 2022 and November 2023.
138	
139	Main outcomes and measures: The main outcomes were the risk (odds ratios [ORs]) for PSP with 95%
140	CIs. Risks for PSP were evaluated by logistic regression models.
141	
142	<b>Results</b> : The copy numbers of $\alpha$ and $\beta$ were associated with the risk of PSP only due to their correlation

143 with H1 and H2, while the copy number of  $\gamma$  was independently associated with the increased risk of 144 PSP. Each additional duplication of  $\gamma$  was associated with 1.10 (95% CI, 1.04-1.17; P = 0.0018) fold of 145 increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition  $\gamma$  duplications 146 displayed a higher odds ratio for PSP: the odds ratio increases from 1.21 (95% CI 1.10-1.33,  $P = 5.47 \times$ 147  $10^{-5}$ ) for H1 $\beta$ 1 $\gamma$ 1 to 1.29 (95%CI 1.16-1.43,  $P = 1.35 \times 10^{-6}$ ) for H1 $\beta$ 1 $\gamma$ 2, 1.45 (95%CI 1.27-1.65, P = $3.94 \times 10^{-8}$ ) for H1 $\beta$ 1 $\gamma$ 3, and 1.57 (95%CI 1.10-2.26,  $P = 1.35 \times 10^{-2}$ ) for H1 $\beta$ 1 $\gamma$ 4. Moreover, H1 $\beta$ 1 $\gamma$ 3 is 148 in linkage disequilibrium with H1c ( $R^2 = 0.31$ ), a widely recognized MAPT sub-haplotype associated 149 150 with increased risk of PSP. The proportion of MAPT sub-haplotypes associated with increased risk of 151 PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1 $\beta$ 1 $\gamma$ 1 to 77% in H1 $\beta$ 1 $\gamma$ 4. 152 **Conclusions and relevance**: This study revealed that the copy number of  $\gamma$  was associated with the risk 153 of PSP independently from H1 and H2. The H1 haplotype with more  $\gamma$  duplications showed a higher 154 odds ratio for PSP and were associated with MAPT sub-haplotypes with increased risk of PSP. These 155 findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.

#### 156 Introduction

157 Progressive supranuclear palsy (PSP) is a neurodegenerative disease with two characteristic clinical features, i.e. postural instability and ocular motor abnormalities<sup>1</sup>. Other symptoms and signs, such as 158 159 cognitive disfunction and problems with swallowing, vary and can get worse over time depending on the distribution of pathology and severity of diseases<sup>2,3</sup>. The main pathology of PSP is the accumulation of 160 tau in the brain, leading to the presence of neurofibrillary tangles and threads along with tufted 161 astrocytes and oligodendroglial coiled bodies<sup>4,5</sup>. An isoform of tau harboring 4 repeats (4R) of 162 microtubule-binding domain is particularly prominent in these tau aggregates<sup>6</sup>. 163 164 The most recognized genetic risk locus for PSP is situated on 17q21.31. The region can be divided into two major haplotypes, H1 and H2, characterized by a 900 Kb inversion found in 20% of Europeans<sup>7</sup>. 165 166 Individuals carrying the H1 haplotype, compared to the H2 haplotype, are more likely to develop PSP,

with an estimated odds ratio (OR) around 5 in Europeans<sup>8,9</sup>. The association was identified through various variants in linkage disequilibrium (LD) with H1 and H2, such as a dinucleotide repeat  $(TG)_n$  in *MAPT* intron 9<sup>10</sup>, a 238-bp deletion in *MAPT* intron 9<sup>7</sup>, and a multitude of single nucleotide variants (SNVs) in this region<sup>8,9</sup>. However, the causal variants underlying the association remain unclear due to numerous SNVs, short insertion/deletions (indels), and structural variations (SVs) introduced by complex genomic rearrangements in 17q.21.31.

Based on LD structure in the *MAPT* region, H1 and H2 haplotypes can be further categorized into more than 20 common sub-haplotypes<sup>11–13</sup>. Among them, H1c, H1d, H1g, and H1o were significantly associated with the increased risk of PSP<sup>11,13</sup>. Particularly, H1c and H1d are nominally associated with

176	measures of severity of tau pathology in PSP cases <sup>11</sup> . However, these sub-haplotypes were inferred from
177	LD structure limited to MAPT gene (~150 Kb) and do not represent the intricacies of structural forms on
178	17q21.31 (~1.5 Mb). To address this limitation, we constructed the ten structural forms of 17q21.31,
179	characterized by the copy numbers of $\alpha$ , $\beta$ , and $\gamma$ (150Kb, 300Kb, and 218Kb; eFigure 1 in
180	Supplement) <sup>14,15</sup> , and evaluated their association with the risk of PSP in this study. We found that the
181	H1 haplotype with more copies $\gamma$ duplication showed an increased risk of PSP. The result is in
182	accordance with the higher portion of H1c and other MAPT sub-haplotypes associated with increased
183	risk of PSP in the H1 haplotypes with more copies of $\gamma$ . Through this study, we gained a better
184	understanding how the haplotypic structure of 17q.21.31 correlates with the risk of PSP.

185

#### 186 Methods

## 187 Study subjects and quality control

All study subjects and WGS data are available on The National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS)<sup>16</sup> under Alzheimer's Disease Sequencing Project (ADSP) Umbrella NG00067.v7<sup>17</sup>. We inferred ancestry of subjects by GRAF-pop<sup>18</sup> and selected 4,618 subjects (1,797 cases and 2,821 controls) of European ancestry for analysis. WGS were performed at 30x coverage (e**Table 1**).

Among 4,618 samples, we filtered 183 samples with abnormally low reads mapped (aligned read depth < 1.7x) to  $\alpha$ ,  $\beta$  or  $\gamma$  region (eFigure 2 in **Supplement**) and ten samples with high genotyping missing rate (> 0.05). Next, 244 related samples inferred by KING<sup>19</sup> (duplicates, monozygotic twins,

196 parent-offsprings, full-siblings, and  $2^{nd}$  degree relatives) were removed.

197	We used the 238-bp deletion between exons 9 and 10 of $MAPT^7$ to determine the H1 and H2
198	haplotypes of each sample. The genotype calls of the 238-bp deletion were obtained from our previous
199	SV work <sup>20</sup> . 75 subjects were removed due to missing or failed genotype of the 238-bp deletion. Given
200	the specification of H1/H2 genotype, determined by the 238 bp deletion, and the copy numbers of $\alpha,\beta$
201	and $\gamma$ , we can ascertain the ten structural forms (eFigure 1 in <b>Supplement</b> ) in each individual. We
202	removed 30 individuals (eFigure 3 and eFigure 4 in Supplement) since their structural forms could not
203	be decided based on the copy numbers of $\alpha$ , $\beta$ and $\gamma$ . This discordance might be due to subjects carrying
204	undiscovered structural forms or genotyping errors on the copy numbers of $\alpha$ , $\beta$ and $\gamma$ . As a result, 4,076
205	subjects (Table 1; $N_{PSP} = 1,684$ , $N_{control} = 2,392$ ) remained for statistical analyses in this study. Of the
206	1,684 individuals with PSP, 1,386 were autopsy confirmed.

	Overall (N = 4,076)	PSP (N = 1,684)	Control (N = 2,392)
Age <sup>a</sup> (SD)	78.49 (8.50)	68.03 (8.17)	81.04 (6.37)
Sex (%)			
Female	2168 (53.19%)	739 (43.88%)	1429 (59.74%)
Male	1908 (46.81%)	945 (56.12%)	963 (40.26%)
H1/H2 status <sup>b</sup> (%)			
H1H1	2958 (72.57%)	1511 (89.73%)	1447 (60.49%)
H1H2	975 (23.92%)	168 (9.98%)	807 (33.74%)
H2H2	143 (3.51%)	5 (0.30%)	138 (5.77%)
Structural forms of 17q21.31 <sup>c</sup> (%)			
Η1β1γ1	2446 (30.00%)	1097 (32.57%)	1349 (28.20%)
Η1β1γ2	1552 (19.04%)	739 (21.94%)	813 (16.99%)
Η1β1γ3	987 (12.11%)	496 (14.73%)	491 (10.26%)
Η1β1γ4	126 (1.55%)	65 (1.93%)	61 (1.28%)
Η1β2γ1	1716 (21.05%)	774 (22.98%)	942 (19.69%)
Η1β3γ1	64 (0.79%)	19 (0.56%)	45 (0.94%)
Η2α1γ1	7 (0.09%)	1 (0.03%)	6 (0.13%)
Η2α1γ2	99 (1.21%)	14 (0.42%)	85 (1.78%)
Η2α2γ1	33 (0.40%)	2 (0.06%)	31 (0.65%)
Η2α2γ2	1122 (13.76%)	161 (4.78%)	961 (20.09%)

## 207 Table 1. Characteristics of PSP cases and controls

<sup>a</sup>1,130 PSP cases and 111 controls have missing age.

<sup>b</sup>H1/H2 status was determined by the genotype of a 238-bp H2 tagging deletion<sup>7</sup>.

<sup>c</sup>Structural forms of 17q21.31 were inferred by expectation-maximization (EM) algorithm.

## 211 Calling the copy numbers $\alpha$ , $\beta$ and $\gamma$ duplications from WGS

212	The	genomic	coordinates	on	HG38	of	α	(chr17:46	5135415-	46289349	θ), β
213	(chr17:4608	37894-46356	5512), and γ	(chr17:	46289349-	46707	123)	were obta	ined fro	m two p	revious
214	studies <sup>14,15</sup>	(eFigure 1 i	n <b>Supplement</b>	). Segn	nental dup	lication	ns can	introduce	mappin	g challen	ges and
215	thus inaccur	rate calling	of the number	of copi	$es^{21-23}$ . To	addre	ss this	, we remo	ved segn	nental duj	plicated
216	regions ins	ide the $\alpha$ ,	$\beta$ and $\gamma$ (eFig	gure 5	in <b>Suppl</b>	ement	) whe	n calculat	ting alig	ned read	depth.
217	Subsequent	ly, the copy	numbers of o	α, β, αι	nd $\gamma$ were	obtaiı	ned ba	used on th	e aligne	d read de	epth on
218	chr17:4613	5415-462032	287,		chr17	:46106	5189-4	6135415,			and
219	chr17:46356	6512-464894	410/chr17:4656	5081-4	6707123,	respe	ctively	v. Copies	of α,	$\beta$ and $\gamma$	y were
220	genotyped	by assessing	g aligned read	l depth	within ea	ach 1	Kb b	in on the	specifie	ed region	s using
221	CNVpytor (	(Version 1.3	$(.1)^{24}$ . Then, we	e emplo	oyed K-me	ans <sup>25</sup> t	to assig	gn an integ	ger copy	number	for α, β
222	and $\gamma$ for the	e 4,076 indiv	viduals.								

223

### 224 Validation of CNV calling

225 To validate the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$  called from WGS, 66 samples were genotyped using 226 TaqMan CNV assay. Overall, the copy number of  $\alpha$ ,  $\beta$ , or  $\gamma$  inferred by aligned read depth from WGS 227 were highly consistent ( $\alpha$ , R = 0.87;  $\gamma$ , R = 0.96) with that from TaqMan assay (eFigure 6 in 228 **Supplement**). The experimental procedure was as follows: Copy number at the  $\alpha$  region (Context 229 Sequence: TTAGTCAATTTCTTAGCCAACCCAT; chr17:46171656-46171680, GRCh38) was 230 determined using a predesigned TaqMan CNV assay (Applied Biosystems Part No. Hs01788222\_cn).

231 Copy number at the  $\gamma$  region (Context Sequence: AGAAAAAAGCATTGACTCCAACCC; 232 chr17:46419867-46419891 and chr17:46637445-46637469, GRCh38) was determined using a custom 233 designed TaqMan CNV assay (Applied Biosystems; Forward Primer: 234 Reverse Primer: CTGCCATCTTGTCGGTGTCA, TGGCACAATGACCATCGAGATT, Reporter 235 Sequence: AAGGGTTGGAGTCAATGCTTTT). For the copy number assay reaction, 20 ng of genomic 236 DNA was combined with TaqMan Master Mix (Applied Biosystems Part No. 4371357), 20X TaqMan 237 CNV assay, and 20x RNase P TaqMan Copy Number Reference Assay (Applied Biosystems Part No. 238 4403328) in a total volume of 20ul. The DNA amplification and quantification were carried out in a 239 QuantStudio 12K Flex instrument (Applied Biosystems) in a 96 well format with the following program: 240 50°C 2min, 95°C 10min followed by 40 cycles of 95°C 15sec, 60°C 1min. The results were analyzed 241 using the TaqMan CopyCaller software (Version 2.0) (Applied Biosystems).

242

#### 243 Determine haplotypic contributions to diploid copy number

For approximately sixty percent of the samples, only one combination of the structural forms (eFigure 1 in **Supplement**) was possible based on the H1 and H2 genotypes, determined by the 238-bp deletion, and the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$ . For the rest of the samples, multiple haplotypic combinations were possible. Therefore, we initially assigned an equal likelihood to all possible haplotypic combinations that were consistent with the detected copy number of  $\alpha$ ,  $\beta$ , and  $\gamma$ . Then, the following expectation-maximization (EM) loop described in the previous study<sup>14</sup> were repeated: from the probabilistic inferences of structural form of 17q21.31 in each sample, we estimated an allele

251	frequency for each structural form of 17q21.31; we then re-estimated the relative likelihood of each
252	combination of haplotypes in each sample, given the population-level allele frequency. In this way, we
253	intended to eliminate haplotypic combinations that are theoretically possible but extremely unlikely
254	given the apparent frequencies of haplotypes as estimated from the rest of the population. The revised
255	probabilistic estimates then allowed a new population-level estimate of haplotype frequencies. We
256	repeated this EM loop process until estimates of haplotype frequency converged. The allele frequency of
257	each structural form of 17q21.31 after convergence were showed in eFigure 1 in Supplement.
258	
259	Phasing for MAPT sub-haplotypes
260	The six SNVs (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521) <sup>11-13</sup> on <i>MAPT</i>
261	were employed to defined the 26 MAPT sub-haplotypes (eTable 2 in Supplement). We phased the six
262	SNVs with other SNVs and indels in chr17:43000000-48000000 to determine the MAPT sub-haplotypes.
263	The SNV genotypes for the study subjects were called in our previous work <sup>26</sup> . Variants were removed if
264	they were monomorphic, did not pass variant quality score recalibration, had an average read depth $\geq$
265	500, or if all calls have DP<10 & GQ<20. Individual calls with a DP<10 or GQ<20 were set to missing.
266	Then, common variants (MAF > 0.01) with $0.25 < ABHet < 0.75$ were phased using SHAPEIT4 <sup>27</sup>
267	(Version 4.2.2).

268

269 Linkage disequilibrium between structural forms of 17q21.31 and MAPT sub-haplotypes

270 To phase the structural forms of 17q21.31 together with *MAPT* sub-haplotypes, we encoded the

271	copy numbers of $\alpha$ , $\beta$ and $\gamma$ as multi-allelic CNVs by a series of surrogate bi-allelic markers with 0/1
272	alleles <sup>14</sup> (eTable 3 in <b>Supplement</b> ). Then, SHAPEIT4 <sup>27</sup> (Version 4.2.2) were used for phasing the copy
273	numbers of $\alpha$ , $\beta$ and $\gamma$ together with SNVs/indels. SNVs and indels insides $\alpha$ , $\beta$ , and $\gamma$ regions
274	(chr17:46087000-46708000) were not included when phasing. After phasing, we calculated the linkage
275	disequilibrium (LD) between structural forms of 17q21.31 and MAPT sub-haplotypes.

276

277 Statistical Analysis

Statistical analyses were performed for the 4,076 individuals ( $N_{PSP} = 1,684$ ,  $N_{control} = 2,392$ ). For the association of the copy numbers of  $\alpha$ ,  $\beta$ , and  $\gamma$  with PSP, logistic regression adjusting for sex and PC1-5 for population substracture was employed. Age was not adjusted in the regression model with following considerations: first, more than half of the PSP cases have age missing (**Table 1**); second, controls (average age, 81) was much older compared to PSP (average age, 63) and well over the mean age-of onset for PSP which is 63 years<sup>28</sup>. Individuals with the H2H2 genotype are imbalanced (5 cases, 138 controls) and with few cases, therefore, statistical analysis for this subgroup was not included.

To evaluate the association of the structural forms of 17q21.31 with PSP, each structural form with allele frequency > 1% is compared with the rest of structural forms using logistic regression model adjusting for sex and PC1-5. To evaluate the association of *MAPT* sub-haplotypes with PSP, each *MAPT* sub-haplotypes with allele frequency > 1% was compared with the rest of sub-haplotypes using logistic regression adjusting for sex and PC1-5.

290

## 291 **Results**

# 292 The copy numbers of $\alpha$ , $\beta$ , and $\gamma$ and PSP risk

293	The H1 and H2 haplotypes are the most prominent genetic risk factor for PSP. Individuals with the
294	H2 haplotype showed significantly lower risk of disease (OR, 0.19; 95%CI, 0.16-0.22; $P = 3.00 \times 10^{-79}$ ).
295	Structural forms of 17q21.31 can be characterized by three large duplications $\alpha$ , $\beta$ , and $\gamma^{14,15}$ . However,
296	their specific contributions to the risk of PSP have not been carefully assessed. In this study, we first
297	evaluated whether the copy numbers of $\alpha$ , $\beta$ , or $\gamma$ are associated to the risk of PSP independently from
298	H1 and H2 (eFigure 7 in <b>Supplement</b> ).
299	We found that each additional copy of $\gamma$ was associated with 1.08 (95%CI, 1.02-1.15; $P = 0.014$ )
300	fold of increased risk of PSP in H1H1 individuals and 1.29 (%95CI, 1.06-1.56; $P = 0.0096$ ) fold of
301	increased risk of PSP in H1H2 individuals ( <b>Table 2</b> ). The association of the copy number of $\gamma$ with PSP
302	in H2H2 individuals was not evaluated since there were only five H2H2 PSP samples. On average, $\boldsymbol{\gamma}$
303	was associated with 1.10 (95% CI, 1.04-1.17; $P = 0.0018$ ) fold of increased risk of PSP after adjusting
304	for sex, PC1-5, and allele count (0, 1, or 2) of the H2 haplotype ( <b>Table 2</b> ). Without adjusting for H2, the
305	effect of $\gamma$ would be neglected (OR, 0.98; 95%CI, 0.93-1.04; $P = 0.60$ , Table. 2) because the H2
306	haplotype has increased copies (usually two copies) of $\gamma$ while displayed significantly lower risk of PSP.
307	

308	Table 2. Association between the copy numbers of $\alpha$ , $\beta$ , $\gamma$ and risk of PSP
-----	--

Model: Sex, PC1-5
(H1H2 carriers, N=975)
(PSP = 168; Control = 807)

	OR (95% CI)	Р	OR (95% CI)	Р	
a	0.91 (0.81-1.02) 0.11		0.81 (0.58-1.11)	0.20	
β	0.91 (0.81-1.02)	0.11	0.79 (0.53-1.15)	0.23	
γ	1.08 (1.02-1.15)	0.014*	1.29 (1.06-1.56)	0.0096*	
	Model: Sex, (N = 4,07 (PSP = 1,684; Con	PC1-5 76) trol = 2,392)	Model: Sex, PC1-5, H2 (N = 4,076) (PSP = 1,684; Control = 2,392)		
	OR (95% CI)	Р	OR (95% CI)	Р	
a	0.57 (0.52-0.63)	$< 2 \times 10^{-16}$ *	0.90 (0.81-1.00)	0.061	
β	1.14 (1.03-1.27)	0.011*	0.90 (0.81-1.01)	0.064	
γ	0.98 (0.93-1.04)	0.60	1.10 (1.04-1.17)	0.0018*	

309 \*Represents statistical significance (< 0.05)

310 We found no significant association for the copy numbers of  $\alpha$  (OR, 0.9; 95%CI 0.81-1.00; P = 311 0.061) and  $\beta$  (OR, 0.9; 95%CI 0.81-1.01; *P* =0.064) with PSP when adjusting the allele count (0, 1, or 2) 312 of H2 (**Table 2**); however, individuals with more copies of  $\alpha$  and  $\beta$  showed slightly lower odds ratio for 313 PSP. Similarly, no significance was observed for the copy numbers of  $\alpha$  and  $\beta$  when association analysis 314 was stratified by H1H1 or H1H2 genotype. Only under the regression model without adjusting H1 and H2, we observed statistically significant association for the copy numbers of  $\alpha$  ( $P < 2 \times 10^{-16}$ ) and  $\beta$  (P =315 316 0.011) with PSP. However, the observed significance mainly arises from their correlation with the H1 317 and H2 haplotypes, i.e., the increased copies (usually two copies) of  $\alpha$  and the absence of  $\beta$  duplication 318 in the H2 haplotype.

319

# 320 Structural forms of 17q21.31 and PSP risk

321	We then evaluated whether the structural forms of 17q21.31, characterized by the $\alpha$ , $\beta$ , and $\gamma$ , show
322	distinct effect on the risk of PSP. We found that the odds ratio for PSP increases from 1.21 (H1 $\beta$ 1 $\gamma$ 1,
323	95%CI 1.10-1.33) to 1.57 (H1 $\beta$ 1 $\gamma$ 4, 95%CI 1.10-2.26) as the copy number of $\gamma$ increases from one copy
324	to four copies ( <b>Table 3</b> ). With an additional copy of $\beta$ , H1 $\beta$ 2 $\gamma$ 1 (OR, 1.24; 95%CI 1.11-1.38; <i>P</i> = 1.87 ×
325	10 <sup>-4</sup> ) displayed similar risk compared to H1 $\beta$ 1 $\gamma$ 1 (OR, 1.21; 95%CI 1.10-1.33; <i>P</i> = 5.47 × 10 <sup>-5</sup> ) regarding
326	PSP. This reaffirmed our finding that the copy number of $\gamma$ was associated with increased risk of PSP
327	independently from H1 and H2, and $\beta$ was not associated with the risk of PSP ( <b>Table 2</b> ; eFigure 7 in
328	Supplement). Besides, all structural forms with H1 background displayed increased risk of PSP and all
329	structural forms with H2 background displayed decreased risk of PSP (Table 3).

330

331 Table 3. Structural forms of 17q21.31 and the risk of PSP

	Freq	uency (%)		
Structural forms	PSP(N = 1,684)	<b>Control</b> (N = 2,392)	Odds ratio	Р
Η1β1γ1	32.57	28.20	1.21 (1.10-1.33)	$5.47  imes 10^{-5}$
Η1β1γ2	21.94	16.99	1.29 (1.16-1.43)	$1.35 imes10^{-6}$
Η1β1γ3	14.73	10.26	1.45 (1.27-1.65)	$3.94 imes10^{-8}$
Η1β1γ4	1.93	1.28	1.57 (1.10-2.26)	$1.35 \times 10^{-2}$
Η1β2γ1	22.98	19.69	1.24 (1.11-1.38)	$1.87  imes 10^{-4}$
Η2α1γ2	0.42	1.78	0.23 (0.12-0.40)	$5.94  imes 10^{-7}$
Η2α2γ2	4.78	20.09	0.19 (0.16-0.23)	$< 2 \times 10^{-16}$

Haplotypes in less than 1% of individuals were excluded.

333 Odds ratio and *P* value were from logistic regression adjusting for PC1-5 and Sex.

334

## 335 Structural forms of 17q21.31 and MAPT sub-haplotypes

336	According to the LD structure in MAPT gene (~150 Kb), 26 MAPT sub-haplotypes can be
337	determined by six haplotype-tagging $SNVs^{11-13}$ (eTable 2 in Supplement). We confirmed the
338	association of H1c (OR 1.79; 95%CI 1.58-2.04; $P = 1.84 \times 10^{-19}$ ), H1d (OR 1.52; 95%CI 1.29-1.79; $P =$
339	$3.89 \times 10^{-7}$ ), and H10 (OR 2.88; 95% CI 2.15-3.89; $P = 2.77 \times 10^{-12}$ ) with PSP ( <b>Table 4</b> ). Moreover, H1g
340	(OR 1.46; 95%CI 1.07-1.98; <i>P</i> = 0.016), which was significant, and H1h (OR 1.36; 95%CI 1.10-1.69; <i>P</i>
341	= 0.0053), which was not significant in the previous study <sup>11</sup> , were both nominal significant in our
342	analysis.

	Sub-haplotype Frequency (%)			
Haplotype	<b>PSP</b> (N = $1,684$ )	<b>Control</b> (N = 2,392)	OR	Р
H1b	16.92	16.99	1.01 (0.90-1.14)	0.84
H1c**	19.6	11.98	1.79 (1.58-2.04)	$1.84 imes10^{-19}$
H1d**	10.39	7.09	1.52 (1.29-1.79)	$3.89  imes 10^{-7}$
H1e	8.76	8.07	1.12 (0.95-1.32)	0.17
H1g*	2.67	1.80	1.46 (1.07-1.98)	0.016
H1h*	5.23	4.03	1.36 (1.10-1.69)	0.0053
H1i	4.69	4.08	1.17 (0.94-1.46)	0.15
H1j	1.28	1.21	1.09 (0.72-1.64)	0.68
H11	2.91	3.22	0.92 (0.71-1.20)	0.55
H1m	2.11	2.07	1.08 (0.78-1.47)	0.64
H1o**	4.13	1.53	2.88 (2.15-3.89)	$2.77 imes10^{-12}$
H1p	1.07	1.36	0.80 (0.52-1.21)	0.30
H1q	1.22	0.86	1.45 (0.92-2.26)	0.11
H1r	1.16	1.30	0.92 (0.60-1.39)	0.69
H1u	2.64	2.34	1.16 (0.86-1.54)	0.33
H1x	1.43	1.36	0.98 (0.67-1.44)	0.93
H1y	1.54	1.51	1.01 (0.70-1.44)	0.98
H1z	1.40	1.00	1.41 (0.93-2.14)	0.11

343 Table 4. *MAPT* sub-haplotypes defined by six SNVs and the risk of PSP

344 *MAPT* sub-haplotypes in less than 1% of individuals were excluded.

\*Represents *MAPT* sub-haplotypes with a  $P \le 0.05$  (nominal significant)

- 346 \*\*Represents *MAPT* sub-haplotypes with a  $P \le 0.0028$  (Bonferroni corrected *P* cutoff for the 18 test 347 performed)
- 348

349 We examined the relationship between the structural forms of 17q21.31 (~1.5 Mb) and MAPT sub-haplotypes (~150 Kb) through LD analysis. We identified two pairs with  $R^2 > 0.1$  (eTable 4 in 350 Supplement): H1 $\beta$ 1 $\gamma$ 3 and H1c (R<sup>2</sup> = 0.31) and H1 $\beta$ 2 $\gamma$ 1 and H1b (R<sup>2</sup> = 0.29). This was confirmed by 351 352 the fact that 70% of H1 $\beta$ 1 $\gamma$ 3 are H1c and 56% of H1 $\beta$ 2 $\gamma$ 1 are H1b (**Fig. 1A**). Moreover, with additional copies of  $\gamma$  in the H1, the proportion of *MAPT* sub-haplotypes with increased risk of PSP (i.e., H1c, H1d, 353 354 H1g, H1h, and H1o) increases from 34% (H1 $\beta$ 1 $\gamma$ 1) to 77% (H1 $\beta$ 1 $\gamma$ 4) (Fig. 1A). In contrast, the 355 proportion of MAPT sub-haplotypes with increased risk of PSP drops from 34% (H1 $\beta$ 1 $\gamma$ 1) to 11% 356  $(H1\beta_{2\gamma}1)$  with an additional copy of  $\beta$  (Fig. 1A). In individuals with H1H2 genotypes, no phasing is 357 needed before comparison, therefore, the association between the structural forms of 17q21.31 and 358 *MAPT* sub-haplotypes can be observed directly without phasing (**Fig. 1B**).



## 359

#### 360 Fig. 1: Structural forms of 17q21.31 and MAPT sub-haplotypes

361 Structural forms of 17q.21.31 in less than 1% of individuals were excluded. Structural forms with H2 362 background are also excluded since there is only one MAPT sub-haplotypes for H2. The number above each bar is the total number of haplotypes for the specific structural form of 17q21.31 and the 363 percentage that are also MAPT sub-haplotypes (H1o, H1c, H1d, H1g, H1h) associated with increased 364 365 risk of PSP. Besides, the percentage of H1 $\beta$ 1 $\gamma$ 3 that is H1c and the percentage of H1 $\beta$ 2 $\gamma$ 1 that is H1b 366 are displayed. A. In phased haplotypes from all samples, the proportion of MAPT sub-haplotypes in each 367 structural form of 17q21.31. B. In H1H2 individuals, the proportion of MAPT sub-haplotypes in each 368 structural form of 17q21.31.

369

## 370 Discussion

371 The H1 and H2 haplotypes on 17q21.31 is the strongest genetic risk factor for PSP<sup>7</sup>. The *MAPT* 

372 gene inside H1 and H2 showed haplotypic-specific expression and was considered as the possible cause

373	of the association <sup>29,30</sup> . Therefore, previous studies have been focused on variants and haplotypic
374	structures inside MAPT and identified sub-haplotypes H1c, H1d, H1o, and H1g, which displayed
375	increased risk of PSP <sup>11,13</sup> . In this study, we went beyond <i>MAPT</i> gene (~150 Kb) and evaluated the
376	association of the structural forms of 17q21.31 (~1.5 Mb), characterized by large duplications $\alpha$ , $\beta$ , and $\gamma$ .
377	with the risk PSP. We found that the copy number of $\gamma$ duplication was associated with increased risk of
378	PSP and structural forms with $\gamma$ duplication (such as H1 $\beta$ 1 $\gamma$ 2, H1 $\beta$ 1 $\gamma$ 3, and H1 $\beta$ 1 $\gamma$ 4) had a higher odds
379	ratio for PSP compared to $H1\beta1\gamma1$ . This is in accordance with the fact that structural forms with
380	additional copies of $\gamma$ (from H1 $\beta$ 1 $\gamma$ 1 to H1 $\beta$ 1 $\gamma$ 4) tended to have more <i>MAPT</i> sub-haplotypes with a
381	significant risk to PSP (i.e., H1c, H1d, H1o, H1g, H1h). Overall, this study provided a first analysis on
382	the association of structural forms of 17q21.31 with the risk of PSP and MAPT sub-haplotypes.
383	It should be noted that the copy numbers of $\alpha$ , $\beta$ , and $\gamma$ are correlated with H1 and H2. When

384 performing the association of the copy numbers of  $\alpha$ ,  $\beta$ , and  $\gamma$  with PSP in individuals with European 385 ancestry, previous studies demonstrated that the 205-Kb  $\beta$  region can only duplicate in the H1 haplotype, 386 the smaller 155-Kb  $\alpha$  region but not the entire  $\beta$  region duplicates in the H2 haplotype, and the 210-Kb  $\gamma$ region usually duplicates only once in the H2 haplotype (eFigure 1 in **Supplement**)<sup>15,31</sup>. Therefore, it is 387 388 important to adjust the status of H1 and H2 and split analysis by individuals with H1H1 and H1H2 389 genotypes when performing the association of  $\alpha$ ,  $\beta$ , and  $\gamma$  with PSP. In terms of genomic position, the  $\alpha$ 390 region is included in  $\beta$  region, and parts of  $\beta$  and  $\gamma$  are overlapping with each other (eFigure 1 in 391 **Supplement**). When performing the association of  $\alpha$  with PSP, we considered whenever there was a  $\beta$ 392 duplication there was also a  $\alpha$  duplication as  $\alpha$  region is included in  $\beta$ . Considering these factors, we

found that only  $\gamma$  is independently associated with risk of PSP, and the associations of  $\alpha$  and  $\beta$  with PSP are due to their correlation with H1 and H2.

395 The influence of structural forms of 17q21.31 on the risk of PSP has never been examined before. In 396 this study, we found that all structural forms with H1 background were association with increased with 397 of PSP. Particularly, H1 with additional  $\gamma$  copies (H1 $\beta$ 1 $\gamma$ 2, H1 $\beta$ 1 $\gamma$ 3, and H1 $\beta$ 1 $\gamma$ 4) displayed a higher 398 odds ratio for PSP compared to H1 $\beta$ 1 $\gamma$ 1. In previous studies of MAPT sub-haplotypes, only a few 399 sub-haplotypes (i.e., H1c, H1d, H1o, and H1g) were associated with increased risk of PSP while other sub-haplotypes displayed no differences against the rest of the population<sup>11,13</sup>. We replicated the 400 401 association of H1c, H1d, H1o and H1g with PSP and identified H1h with nominal significance. 402 Furthermore, we showed that the H1 haplotype with additional  $\gamma$  copies had more *MAPT* sub-haplotypes 403 that have higher risk of PSP (H1c, H1d, H1o, H1g and H1h), the proportion of MAPT sub-haplotypes 404 associated with PSP increased from 34% in H1 $\beta$ 1 $\gamma$ 1 to 77% in H1 $\beta$ 1 $\gamma$ 4.

#### 405 Limitations

Despite our finding of the importance of the copy number of  $\gamma$  duplication in the risk of PSP, there are a few limitations in the current study. First, all our PSP samples are of European ancestry. It is important to collect samples from other ancestries to validate the discovery in a genetically diverse background. Second, not all PSP cases are pathologically confirmed: of the 1,684 individuals with PSP, 1,386 were autopsy confirmed. Finally, the association analysis needed to be replicated in an independent dataset. Currently, the available resource for whole genome sequencing data in PSP is limited. Therefore, future study focusing on  $\alpha$ ,  $\beta$ , and  $\gamma$  regions using CNV array to replicate the findings

413 in a large independent cohorts might be helpful.

414

415	Conclusions
416	In this study of 4076 subjects ( $N_{PSP} = 1,684$ , $N_{control} = 2,392$ ), we found that $\gamma$ duplication was
417	associated with increased risk (OR, 1.10; 95% CI, 1.04-1.17; $P = 0.0018$ ) of PSP. In accordance with
418	this finding, the structural forms with additional copies of $\gamma$ (H1 $\beta$ 1 $\gamma$ 2 [OR, 1.29; 95%CI 1.16-1.43; P =
419	$1.35 \times 10^{-6}$ ], H1 $\beta$ 1 $\gamma$ 3 [OR, 1.45; 95% CI 1.27-1.65; P = $3.94 \times 10^{-8}$ ], H1 $\beta$ 1 $\gamma$ 4[OR, 1.57; 95% CI 1.10-2.26]
420	$P = 1.35 \times 10^{-2}$ ]) showed higher odds ratio for PSP compared to H1 $\beta$ 1 $\gamma$ 1 (OR, 1.21; 95%CI 1.10-1.33; P
421	= $5.47 \times 10^{-5}$ ) and had higher proportion of <i>MAPT</i> sub-haplotypes associated with increased risk of PSP
422	(i.e., H1c, H1d, H1g, H1o, and H1g).
423	
424	Declarations
425	Ethics approval and consent to participate
426	
427	Consent for publication
428	Not applicable.
429	
430	Availability of data and materials
431	NIAGADS Data Sharing Service ( <u>https://dss.niagads.org/</u> )
432	

433 *Competing interests* 

434	Laura Molina-Porcel received income from Biogen as a consultant in 2022. Gesine Respondek is
435	now employed by Roche (Hoffmann-La Roche, Basel, Switzerland) since 2021. Her affiliation whilst
436	completing her contribution to this manuscript was German Center for Neurodegenerative Diseases
437	(DZNE), Munich, Germany. Thomas G Beach is a consultant for Aprinoia Therapeutics and a Scientific
438	Advisor and stock option holder for Vivid Genomics. Huw Morris is employed by UCL. In the last 12
439	months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics and Amylyx; lecture
440	fees/honoraria - BMJ, Kyowa Kirin, Movement Disorders Society. Huw Morris is a co-applicant on a
441	patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease
442	(PCT/GB2012/052140). Giovanni Coppola is currently an employee of Regeneron Pharmaceuticals.
443	Alison Goate serves on the SAB for Genentech and Muna Therapeutics.

- 444
- 445 Funding

446 This work was supported by NIH 5UG3NS104095, the Rainwater Charitable Foundation, and 447 CurePSP. HW and PLC are supported by RF1-AG074328, P30-AG072979, U54-AG052427 and 448 U24-AG041689. TSC is supported by NIH K08AG065519 and the Larry L Hillblom Foundation 449 2021-A-005-SUP. YQS, AT, and JYT are supported by RF1-AG074328. KF was supported by CurePSP 450 685-2023-06-Pathway and K01 AG070326. MG is supported by P30 AG066511. BFG and KLN are 451 supported by P30 AG072976 and R01 AG080001. TGB and GES are supported by P30AG072980. IR is 452 supported by 2R01AG038791-06A, U01NS100610, R25NS098999, U19 AG063911-1 and 453 1R21NS114764-01A1. OR is support by U54 NS100693. DG is supported by P30AG062429. ALB is

454 supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. BLM is supported 455 by P01 AG019724, R01 AG057234 and P0544014. VMV is supported by P01-AG-066597, 456 P01-AG-017586. HRM is supported by CurePSP, PSPA, MRC, and Michael J Fox Foundation. RDS is 457 supported by CurePSP, PSPA, and Reta Lila Weston Trust. JFC is supported by R01 AG054008, R01 458 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable 459 Foundation / Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane 460 Martin. AMG is supported by the Tau Consortium and U54-NS123746. YYL is supported by 461 U54-AG052427; U24-AG041689. LSW is supported by U01AG032984, U54AG052427, and 462 U24AG041689. GUH was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research 463 Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for 464 Systems Neurology (EXC 2145 SyNergy - ID 390857198); Deutsche Forschungsgemeinschaft (DFG, 465 HO2402/18-1 MSAomics); German Federal Ministry of Education and Research (BMBF, 01KU1403A 466 EpiPD; 01EK1605A HitTau; 01DH18025 TauTherapy). DHG is supported by 3UH3NS104095, Tau 467 Consortium. WPL is supported by RF1-AG074328; P30-AG072979; U54-AG052427; U24-AG041689. 468 Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30 469 AG19610 and P30AG072980), the Arizona Department of Health Services (contract 211002, Arizona 470 Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 471 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for 472 Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by NIA grants P50 473 AG016574, CurePSP Foundation, and support from Mayo Foundation.

474

## 475 Acknowledgements

476 This project is supported by CurePSP, courtesy of a donation from the Morton and Marcine 477 Friedman Foundation. We are indebted to the Biobanc-Hospital Clinic-FRCB-IDIBAPS and Center for 478 Neurodegenerative Disease Research at Penn for samples and data procurement. The PSP genetics study 479 group is a multisite collaboration including: German Center for Neurodegenerative Diseases (DZNE), 480 Munich; Department of Neurology, LMU Hospital, Ludwig-Maximilians-Universität (LMU), Munich, 481 Germany (Franziska Hopfner, Günter Höglinger); German Center for Neurodegenerative Diseases 482 (DZNE), Munich; Center for Neuropathology and Prion Research. LMU Hospital, 483 Ludwig-Maximilians-Universität (LMU), Munich, Germany (Sigrun Roeber, Jochen Herms); 484 Justus-Liebig-Universität Gießen, Germany (Ulrich Müller); MRC Centre for Neurodegeneration 485 Research, King's College London, London, UK (Claire Troakes); Movement Disorders Unit, Neurology 486 Department and Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, 487 University of Barcelona, Barcelona, Catalonia, Spain (Ellen Gelpi; Yaroslau Compta); Department of 488 Neurology and Netherlands Brain Bank, Erasmus Medical Centre, Rotterdam, The Netherlands (John C. 489 van Swieten); Division of Neurology, Royal University Hospital, University of Saskatchewan, Canada 490 (Alex Rajput); Australian Brain Bank Network in collaboration with the Victorian Brain Bank Network, 491 Australia (Fairlie Hinton), Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain (Justo García de Yebenes). The acknowledgement of PSP cohorts is listed below, whereas the 492 493 acknowledgement of ADSP cohorts for control samples can be found in the supplementary materials.

The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: https://gtexportal.org/home/datasets the GTEx Portal on 1/27/2022. We also thank to Drs. Murray Grossman and Hans Kretzschmar for their valuable contribution to this work.

499 AMP-AD (sa000011) data: Mayo RNAseq Study- Study data were provided by the following sources: 500 The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven 501 G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the 502 Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection 503 was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 504 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, 505 NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data 506 includes samples collected through the Sun Health Research Institute Brain and Body Donation Program 507 of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of 508 Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's 509 Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's 510 Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's 511 Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 512 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's 513 Research.

514 <u>PSP-NIH-CurePSP-Tau (sa000015) data</u>: This project was funded by the NIH grant UG3NS104095 and 515 supported by grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the 516 Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo 517 Clinic Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence 518 (NINDS P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of 519 Pennsylvania are supported by NIA grant P01AG017586.
520 PSP-CurePSP-Tau (sa000016) data: This project was funded by the Tau Consortium, Rainwater

521 Charitable Foundation, and CurePSP. It was also supported by NINDS grant U54NS100693 and NIA 522 grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the Reta Lila 523 Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo Clinic 524 Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS 525 P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of Pennsylvania 526 are supported by NIA grant P01AG017586. Tissues were received from the Victorian Brain Bank, supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian 527 528 Forensic Institute of Medicine and funded in part by Parkinson's Victoria and MND Victoria. We are 529 grateful to the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona for 530 the provision of human biological materials (or specific description, e.g. brain tissue, cerebrospinal 531 fluid). The Brain and Body Donation Program is supported by the National Institute of Neurological 532 Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and 533 Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core

534	Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research
535	Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the
536	Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research.
537	Biomaterial was provided by the Study Group DESCRIBE of theClinical Research of the German
538	Center for Neurodegenerative Diseases (DZNE).
539	PSP_UCLA (sa000017) data: Thank to the AL-108-231 investigators, Adam L Boxer, Anthony E Lang,
540	Murray Grossman, David S Knopman, Bruce L Miller, Lon S Schneider, Rachelle S Doody, Andrew
541	Lees, Lawrence I Golbe, David R Williams, Jean-Cristophe Corvol, Albert Ludolph, David Burn,
542	Stefan Lorenzl, Irene Litvan, Erik D Roberson, Günter U Höglinger, Mary Koestler, Cliff ord R Jack Jr,
543	Viviana Van Deerlin, Christopher Randolph, Iryna V Lobach, Hilary W Heuer, Illana Gozes, Lesley
544	Parker, Steve Whitaker, Joe Hirman, Alistair J Stewart, Michael Gold, and Bruce H Morimoto.
545	Authors' information
546	
547	Authors' contribution

548 Study design: TSC, DD, GUH, JYT, DHG, GDS, and WPL. Sample collection, brain biospecimens,

- 549 and neuropathological examinations: TSC, CM, LM, AR, PPDD, NLB, MG, LDK, JCVS, ED, BFG,
- 550 KLN, CT, JGdY, ARG, TM, WHO, GR, UM, FH, TA, SR, PP, AB, AD, ILB, TGC, GES, LNH, IL, RR,
- 551 OR, DG, ALB, BLM, WWS, VMVD, EBL, CLW, HM, JH, RdS, JFC, AMG, GC, and DHG. Genotype
- or phenotype acquisition: HW, TSC, VP, LVB, KF, AN, LSW, DHG, GDS, and WPL. Variant detection
- and variant quality check: HW, TSC, VP, LVB, KF, YYL, and WPL. Statistical analyses and

- 554 interpretation of results: HW, YQS, AT, TSC, KF, AN, JYT, DHG, GDS, and WPL. Experimental
- validation: BAD and PLC. Draft of the manuscript: HW, GDS, and WPL. All authors read, critically
- 556 revised, and approved the manuscript.

## 557 **References**

- Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. *Clin Exp Optom*.
   2011;94(2):150-160. doi:10.1111/j.1444-0938.2010.00504.x
- Lukic MJ, Respondek G, Kurz C, et al. Long-Duration Progressive Supranuclear Palsy: Clinical
   Course and Pathological Underpinnings. *Ann Neurol*. 2022;92(4):637-649.
- 3. Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive
  supranuclear palsy. *Mov Disord*. 2019;34(8):1144-1153.
- 4. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for
  Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology*.
  1994;44(11):2015-2015.
- 567 5. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive 568 supranuclear palsy. *Acta Neuropathol (Berl)*. 2020;140(2):99-119. doi:10.1007/s00401-020-02158-2
- 569 6. Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, Höglinger GU. Evolving
  570 concepts in progressive supranuclear palsy and other 4-repeat tauopathies. *Nat Rev Neurol*.
  571 2021;17(10):601-620. doi:10.1038/s41582-021-00541-5
- 572 7. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with
  573 progressive supranuclear palsy. *Hum Mol Genet*. 1999;8(4):711-715.
- 8. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk
  of the tauopathy progressive supranuclear palsy. *Nat Genet*. 2011;43(7):699-705.
- Wang H, Chang TS, Dombroski BA, et al. Whole-Genome Sequencing Analysis Reveals New
  Susceptibility Loci and Structural Variants Associated with Progressive Supranuclear Palsy. *medRxiv*.
  Published online 2023:2023-12.
- 579 10. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of  $\tau$  in 580 progressive supranuclear palsy. *Ann Neurol*. 1997;41(2):277-281. doi:10.1002/ana.410410222
- 11. Heckman MG, Brennan RR, Labbé C, et al. Association of MAPT subhaplotypes with risk of
   progressive supranuclear palsy and severity of tau pathology. *JAMA Neurol.* 2019;76(6):710-717.
- 12. Heckman MG, Kasanuki K, Brennan RR, et al. Association of MAPT H1 subhaplotypes with
   neuropathology of lewy body disease. *Mov Disord*. 2019;34(9):1325-1332. doi:10.1002/mds.27773
- 585 13. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype

- association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.
   *J Med Genet*. 2005;42(11):837-846.
- 588 14. Boettger LM, Handsaker RE, Zody MC, McCarroll SA. Structural haplotypes and recent evolution
  589 of the human 17q21. 31 region. *Nat Genet*. 2012;44(8):881-885.
- 590 15. Steinberg KM, Antonacci F, Sudmant PH, et al. Structural diversity and African origin of the 17q21.
  591 31 inversion polymorphism. *Nat Genet*. 2012;44(8):872-880.
- 592 16. Kuzma A, Valladares O, Cweibel R, et al. NIAGADS: The NIA Genetics of Alzheimer's Disease
  593 Data Storage Site. *Alzheimers Dement*. 2016;12(11):1200-1203. doi:10.1016/j.jalz.2016.08.018
- 594 17. Beecham GW, Bis JC, Martin ER, et al. The Alzheimer's Disease Sequencing Project: study design
  595 and sample selection. *Neurol Genet*. 2017;3(5).
- Ia. Jin Y, Schaffer AA, Feolo M, Holmes JB, Kattman BL. GRAF-pop: a fast distance-based method to
   infer subject ancestry from multiple genotype datasets without principal components analysis. *G3 Bethesda Md*. 2019;9(8):2447-2461.
- Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
   inference in genome-wide association studies. *Bioinformatics*. 2010;26(22):2867-2873.
- Wang H, Dombroski BA, Cheng PL, et al. Structural Variation Detection and Association Analysis
   of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects.
   *medRxiv*. Published online 2023.
- 21. Cantsilieris S, Western PS, Baird PN, White SJ. Technical considerations for genotyping
  multi-allelic copy number variation (CNV), in regions of segmental duplication. *BMC Genomics*.
  2014;15(1):329. doi:10.1186/1471-2164-15-329
- 407 22. Handsaker RE, Van Doren V, Berman JR, et al. Large multiallelic copy number variations in humans.
   408 Nat Genet. 2015;47(3):296-303.
- 609 23. Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the
  610 human genome. *Am J Hum Genet*. 2005;77(1):78-88.
- 611 24. Suvakov M, Panda A, Diesh C, Holmes I, Abyzov A. CNVpytor: a tool for copy number variation
  612 detection and analysis from read depth and allele imbalance in whole-genome sequencing.
  613 *Gigascience*. 2021;10(11):giab074.
- 614 25. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python. J Mach
   615 Learn Res. 2011;12:2825-2830.

- 616 26. Lee WP, Choi SH, Shea MG, et al. Association of Common and Rare Variants with Alzheimer's
  617 Disease in over 13,000 Diverse Individuals with Whole-Genome Sequencing from the Alzheimer's
  618 Disease Sequencing Project. *medRxiv*. Published online 2023:2023-09.
- 619 27. Delaneau O, Zagury JF, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and
   620 integrative haplotype estimation. *Nat Commun.* 2019;10(1):5436.
- 28. Rajput A, Rajput AH. Progressive Supranuclear Palsy: Clinical Features, Pathophysiology and
   Management. *Drugs Aging*. 2001;18(12):913-925. doi:10.2165/00002512-200118120-00003
- 29. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered
  regulation of tau gene expression in progressive supranuclear palsy. *Hum Mol Genet*.
  2005;14(21):3281-3292.
- 30. Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of
  exon 10 at the human MAPT locus. *Hum Mol Genet*. 2006;15(24):3529-3537.
- Sudmant PH, Kitzman JO, Antonacci F, et al. Diversity of human copy number variation and
   multicopy genes. *Science*. 2010;330(6004):641-646.